Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.75 |
| ▸ | HPGD | P15428 | 8/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | GFER | P55789 | 2/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.66 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072642 | 0.89 | ALDH1A1 (0.81) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL8978517 | 0.84 | ALDH1A1 (0.75) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL13729062 | 0.83 | TDP1 (0.75) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL8978622 | 0.82 | HPGD (0.79) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL8930945 | 0.81 | ALDH1A1 (0.62) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL8978542 | 0.81 | ALDH1A1 (0.69) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL8978598 | 0.79 | ALDH1A1 (0.66) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL13983421 | 0.79 | ALDH1A1 (0.56) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL12768250 | 0.78 | ALDH1A1 (0.63) | ALDH1A1HPGDKMT2AMEN1KDM4E | |
| SCHEMBL8978534 | 0.75 | ALDH1A1 (1.00) | ALDH1A1HPGDKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
| US-5489598-A | INHIBITS ADHESION OF MAC-1 TO ENDOTHELIAL CELLS, USEFUL FOR TREATING GASTRITIS INDUCED BY NONSTEROIDANTIINFLAMMATORY DRUGS IMFLAMMATORY BOWEL DISEASE OF ULCERATIVE COLITIS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | ALDH1A1 151/4885HPGD 114/4885KMT2A 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.